About: Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Sector: Healthcare
Industry: Biotechnology
Latest price: $6.48 (-0.61%)
EPRXNASDAQEupraxia Pharmaceuticals Inc. Common Stock
Loading watchlist status…
Eupraxia Pharmaceuticals Inc. Common Stock share price
EPRX price activity
Last Price
Change (24hr)
USD (%)
Volume
-
Volume (4w avg)
-
Previous Close
N/A
Last Trade
EPRX price performance
-1.07%
5D
-3.14%
1M
-14.17%
YTD
20.92%
1Y
EPRX price fundamentals
N/A
Shares Issued
N/A
Earnings Per Share (EPS)
N/A
Dividends Per Share (DPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
US-NASDAQ rank
N/ASector Rank
N/AEPRX details
EPRX Market Signals